OraSure Technologies (OSUR) Q3 2026 earnings review
OraSure lifts its factory profit, but cash burn continues
OraSure Technologies, the maker of rapid medical tests and sample collection kits, lifted its profit margins while its quarterly sales levelled off. Total revenue rose 14% from last year's depressed level to $31 million, and gross margin climbed to 45% after the company consolidated its factories. Chief executive Carrie Eglinton Manner highlighted initial orders for two newly launched products, yet the company still burned $11 million of operating cash in the quarter by our math.
| Core business revenue | $30.9M +14% from a year ago (+1% from last quarter) |
|---|---|
| Gross margin | 45.2% up 1.7 percentage points from a year ago and last quarter |
| Operating loss, excluding one-offs | $10.2M narrowed from $12.7M a year ago and $14.7M last quarter |
| Q4 revenue outlook | $30.0–32.0M middle of the range: +16% from a year ago, flat vs Q3 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because factory savings and lower overhead are offset by ongoing cash burn and flat sequential sales. Gross margin beat the company's plan and research and overhead spending fell, narrowing the operating loss excluding one-offs to $10 million. One caution: the fourth-quarter outlook keeps revenue at $30 million to $32 million, leaving a wide gap against management's prior pledge to reach break-even operating cash flow entering 2027.
The question now is whether the newly launched urine-collection kit and Ebola test can bring in enough sales to cover the company's fixed costs while its delayed sexual-health self-test undergoes a new clinical trial. Either the new products scale up in 2027 to fill the factory, or the company must cut operating expenses again to stop the cash drain. Fourth-quarter cash flow and the 2027 revenue range next quarter will tell.
🐂 Bull Case
Factory Consolidation Lifted Gross Margin Past Plan
OraSure spent the last two years closing four global sites and moving production into its main plant in Bethlehem, Pennsylvania. Three months ago, management forecast that third-quarter gross margin would stay near the second quarter's 43.5%.
Instead, gross margin rose 1.7 percentage points from both a year ago and last quarter to 45.2%, or 45.9% excluding one-offs. The company said the gain was "primary a result of operational efficiencies driving better absorption of fixed overhead costs, partially offset by product mix". Cost of making the products fell to 54.8% of revenue from 56.5% a year ago.
This matters because management had warned that launching two new products in the second half could drag margins down during their early production ramp. Beating the plan while shipping initial orders of both products shows the factory savings are outrunning early launch costs.
What to watch: fourth-quarter gross margin in the next earnings release. Holding above 45% as new product shipments grow would confirm the plant can move toward management's 50% long-term target.
Sample Collection Rebounded on Commercial Orders
Sample Management Solutions, the unit that sells kits for collecting saliva, blood and urine, had been stuck below $10 million a quarter since losing a large consumer genetics customer last year. Chief executive Carrie Eglinton Manner wants new collection devices to restart growth.
In the third quarter, the unit's sales jumped 21% from a year ago and 27% from last quarter to $12.5 million. The diagnostic maker attributed the rise to "key commercial customer growth and timing of specific orders". It also shipped the first orders of Colli-Pee Dx, an at-home urine collection kit cleared in June for sexually transmitted infection testing on Roche laboratory machines.
The rebound matters because it offset a sequential drop in the diagnostics unit and kept total revenue near $31 million. However, the company noted order timing helped the quarter, so part of the jump may not repeat immediately.
What to watch: Sample Management Solutions revenue in the fourth-quarter report. Staying above $11 million would show commercial demand is growing beyond one-time order timing.
Lower Research and Overhead Costs Narrowed the Loss
OraSure's operating expenses have been far too high for its revenue base, and management promised last quarter that general and administrative overhead would fall in the third quarter as shareholder-activism costs ended.
Overhead did fall: general and administrative spending dropped 17% from last quarter, or 8.3 percentage points of revenue by our math, to $12.0 million. Research and development spending also fell 12.6 percentage points of revenue from a year ago to $7.6 million after the company paused its molecular self-test trial. Together with higher gross profit, that cut the operating loss excluding one-offs to $10.2 million from $14.7 million last quarter.
That narrows the gap, but total operating expenses of $26.9 million still Approaches double the $14.0 million of gross profit. One quarter of lower overhead fades the cost concern without solving it.
What to watch: research and development spending once the new clinical trial for the chlamydia and gonorrhea self-test begins. A jump back above $10 million a quarter would widen the operating loss again.
🐻 Bear Case
Cash Burn Worsened Ahead of the Break-Even Deadline
"Our third quarter results demonstrate the continued execution of our strategy," chief executive Carrie Eglinton Manner said, pointing to cost cuts and margin gains. Management previously committed to reaching break-even operating cash flow as the company enters 2027.
The cash flow statement moved the other way. By our math, subtracting six-month figures from the nine-month report shows OraSure burned $10.9 million of cash in operations during the third quarter, worse than the $9.9 million burned in the second quarter. Including $1.7 million of factory equipment purchases, free cash flow was negative $12.5 million, and total cash fell from $160.6 million to $148.2 million.
- Third-quarter operating cash flow: negative $10.9 million by our math, vs negative $10.1 million a year ago
- Nine-month operating cash flow: negative $34.7 million, including an $8.7 million cash drain from uncollected customer bills
- Fourth-quarter revenue outlook: $30 million to $32 million, flat with the third quarter's $30.9 million
Because fourth-quarter revenue is planned to stay flat, the business cannot close a $10 million quarterly operating loss through sales growth alone as 2027 begins.
What to watch: fourth-quarter operating cash flow in the full-year report. Even if customer collections improve, another outflow near $10 million would mean the company missed its break-even target entering 2027.
New Launches Lack Revenue Figures and Timeline
OraSure's growth plan rests on new diagnostic devices: Colli-Pee Dx for urine collection, the OraQuick Ebola 2.0 rapid test, the acquired Sickle SCAN blood test, and the Sherlock molecular self-test for chlamydia and gonorrhea (InteliQuick CT/NG). Last quarter, management withdrew the FDA application for the CT/NG self-test to run a new clinical trial.
In the third quarter, Manner said the Colli-Pee Dx and Ebola 2.0 launches were able to "quickly translate into initial orders during the third quarter", and the company noted Sickle SCAN helped lift diagnostics revenue. However, the release gave no dollar or unit figures for any of the three products, and it did not mention the withdrawn CT/NG self-test or when its new clinical trial will start.
Without dollar disclosures, investors cannot tell if the new products are big enough to replace older public-health lines. And without a trial timeline, the $17 million intangible asset tied to the Sherlock acquisition remains at risk of a write-down.
What to watch: management's remarks on the conference call and in the quarterly filing for a specific start date on the CT/NG clinical trial and any dollar figures on initial launch orders.
Diagnostics Dropped 13% From Last Quarter
Diagnostics, OraSure's largest unit, sells rapid tests for HIV, hepatitis C and Ebola heavily to government and donor-funded public health programmes such as PEPFAR and the CDC.
The company highlighted that third-quarter diagnostics sales rose 16% from a year ago to $16.8 million on "higher HIV and HCV revenues and the addition of BioMedomics’ Sickle SCAN® sales". That comparison is against last year's trough of $14.5 million, when international HIV orders dropped. Compared with the second quarter's $19.4 million, diagnostics revenue fell 13% by our math.
The drop from last quarter confirms that the second quarter's jump was helped by customer budget-cycle buying rather than a steady climb in demand. Public-health funding remains uneven from quarter to quarter.
What to watch: fourth-quarter diagnostics revenue against last year's $15.1 million trough. A reading below $17 million would show the core testing business is still not growing past its second-quarter level.
💲 Other KPIs
Customer bills waiting to be collected rose 37% from $22.2 million at the end of 2025, even though quarterly revenue of $30.9 million is only slightly above the first half's pace. That build-up tied up $8.7 million of cash over the first nine months and was the main working-capital drag on operating cash flow.
Share count fell 5.5% from 73.0 million a year ago because of earlier buybacks. However, OraSure spent $7.0 million on buybacks across the first nine months — the exact same cumulative total it reported after six months — meaning the company bought back no shares in the third quarter as it conserved cash.
The carrying value of OraSure's minority stake in diagnostics partner Sapphiros fell from $26.0 million at the end of 2025 after the company recorded a $0.6 million loss on the investment this quarter and $2.2 million over nine months. Management excludes these ongoing losses from its non-GAAP profit figures.
🔮 Guidance
New. The plan calls for about 15.8% growth from a year ago at the $31.0 million middle of the range by our math, and 4.7% growth for the full year 2026. Like the third quarter, the high year-over-year percentage comes against last year's fourth-quarter trough of $26.8 million; compared with the third quarter, the midpoint is flat (+0.3%).
Unchanged in direction, with a new floor. The company expects an "acceleration of year-over-year growth in total revenues for the full year 2027 as compared to the full year 2026", which sets a floor above 2026's planned 4.7% rate (about $120.5 million). The release did not give a dollar range or repeat the prior commitment to break-even operating cash flow entering 2027.
❓ Key Questions
Is the 2027 cash-flow break-even pledge still intact?
Management previously committed to reaching break-even operating cash flow entering 2027. With third-quarter operating cash burn at $10.9 million by our math and fourth-quarter revenue planned flat at $30–32 million, is that timeline still achievable without new cost cuts?
When will the new CT/NG clinical trial start?
After withdrawing the FDA submission for the Sherlock chlamydia and gonorrhea self-test in July, the press release did not mention the programme. What is the trial's start date, cost and expected submission quarter?
How large were initial Colli-Pee Dx and Ebola orders?
The company reported initial third-quarter sales for both newly cleared products but gave no dollar or unit numbers. How much revenue did they contribute in the third quarter, and how much is built into the fourth-quarter outlook?
Why did uncollected customer bills jump 37% this year?
Accounts receivable rose from $22.2 million at year-end to $30.4 million in the third quarter, draining $8.7 million of cash. Is this tied to slow payments from international distributors, and will it reverse in the fourth quarter?